Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California San Francisco, 505 Parnassus Avenue, M-917, Box 0624, San Francisco, CA 94143-0624, USA; Department of Critical Care Medicine, Alberta Health Services and University of Calgary, Calgary, Canada.
Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California San Francisco, 505 Parnassus Avenue, M-917, Box 0624, San Francisco, CA 94143-0624, USA.
Clin Chest Med. 2024 Dec;45(4):809-820. doi: 10.1016/j.ccm.2024.08.003. Epub 2024 Sep 20.
Biomarkers are an important tool aiding researchers in the study of acute respiratory distress syndrome (ARDS). Mechanisms involving injury to the alveolar-capillary membrane, endothelium and epithelium resulting in lung inflammation and alterations in coagulation pathways have been validated in human trials and have been used to discover promising phenotypes that share similar characteristics and differential treatment responses. The emergence of powerful point-of-care technologies will enable the prospective study of biomarkers for future enrichment trials with the goal of transforming biomarkers into the clinical realm to inform delivery of personalized medicine at the bedside.
生物标志物是研究急性呼吸窘迫综合征（ARDS）的重要工具。在临床试验中，已经验证了涉及肺泡-毛细血管膜、内皮和上皮损伤导致肺炎症和凝血途径改变的机制，并已用于发现具有相似特征和不同治疗反应的有前途的表型。强大的即时检测技术的出现将使生物标志物的前瞻性研究能够用于未来的富集试验，目标是将生物标志物转化为临床领域，以便在床边提供个性化医疗。
